Likewise, the anti-NKG2A-mAb-IgG4 targets inhibitory NKG2A receptors on NK cells and disrupts their interaction with HLA-E (nonclassical MHC-I), strengthening NK-mediated anti-tumor responses24,25. This evidence concerns the gene HLA-E and neoplasm.